Review

How Microbes Affect Depression: Underlying Mechanisms via the Gut–Brain Axis and the Modulating Role of Probiotics

Kazunori Suda and Kazunori Matsuda *

Yakult Central Institute, 5-11 Izumi, Kunitachi-shi, Tokyo 186-8650, Japan; kazunori-suda@yakult.co.jp
* Correspondence: kazunori-matsuda@yakult.co.jp

Abstract: Accumulating evidence suggests that the gut microbiome influences the brain functions and psychological state of its host via the gut–brain axis, and gut dysbiosis has been linked to several mental illnesses, including major depressive disorder (MDD). Animal experiments have shown that a depletion of the gut microbiota leads to behavioral changes, and is associated with pathological changes, including abnormal stress response and impaired adult neurogenesis. Short-chain fatty acids such as butyrate are known to contribute to the up-regulation of brain-derived neurotrophic factor (BDNF), and gut dysbiosis causes decreased levels of BDNF, which could affect neuronal development and synaptic plasticity. Increased gut permeability causes an influx of gut microbial components such as lipopolysaccharides, and the resultant systemic inflammation may lead to neuroinflammation in the central nervous system. In light of the fact that gut microbial factors contribute to the initiation and exacerbation of depressive symptoms, this review summarizes the current understanding of the molecular mechanisms involved in MDD onset, and discusses the therapeutic potential of probiotics, including butyrate-producing bacteria, which can mediate the microbiota–gut–brain axis.

Keywords: gut microbiome; gut–brain axis; depression; probiotics

1. Introduction

Major depressive disorder (MDD) is a common but serious mental disorder characterized by symptoms such as depressed mood, anhedonia, fatigue, anxiety, irritability, insomnia, altered appetite, and suicidal ideation. It has been reported that around 280 million people worldwide suffer from MDD [1], and the results of a global burden of disease study revealed that, based on years lost to disability, depression ranks among the top 10 disabling diseases [2], indicating that MDD profoundly affects the individual’s quality of life worldwide. Although the etiologies underlying this disorder remain unclear, several hypotheses have been proposed to explain the underlying mechanisms of its pathogenesis. The monoamine hypothesis, which holds that depression arises from monoamine deficiency, has been the basis for the development of selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenaline reuptake inhibitors, widely used as antidepressants [3]. It has been observed that the increase in monoamines, which is the pharmacological effect of SSRIs, appears immediately after administration, whereas there is a latency in the response to the antidepressants for several weeks. The monoamine hypothesis is now considered to be part of the pathogenic mechanism of depression or its result [4]. It has become evident that multiple factors are intricately involved in the pathogenesis of depression, and disorders of the hypothalamus-pituitary-adrenal (HPA) axis involved in stress response, and neurogenesis/neuroplasticity dysfunction involving brain-derived neurotrophic factors (BDNF), have both been proposed as new hypotheses for the cause of depression.

Recent research has revealed that the gut microbiome influences human brain functions via the “gut–brain axis”, the bidirectional communication between the brain and the gut, which includes humoral and neural pathways. With the elucidation, in the psychiatric context, of the impact of the gut microbiota on human homeostasis via the gut–brain axis,
the concept of a “microbiota–gut–brain (MGB) axis” has evolved [5]. Animal studies have revealed that gut dysbiosis is involved in abnormal stress response, reduced neurogenesis, and neuroinflammation in the host, all of which can be linked to the onset of MDD. Experiments involving germ-free mice that received fecal microbiota transplantation (FMT) from MDD patients strongly indicated that the gut microbiota contributed to the onset of depressive symptoms [6,7]. Alterations in the gut microbiota composition have been investigated in several human studies. Knudsen et al. conducted a systematic review of 17 studies analyzing the gut microbiota of MDD patients, and identified an increase in *Eggerthella*, *Atopobium*, and *Bifidobacterium* (all of the *Actinobacteria* phylum), and a decrease in *Faecalibacterium*, as common features in such patients [8]. *Faecalibacterium* is known as a main component of butyrate-producing bacteria in the gut, and butyrate has been reported to maintain BDNF levels and neurogenesis in the hippocampus, and improve depressive behavior. In the case of *Bifidobacterium*, several reports have indicated an opposite pattern to that found in [8]. Aizawa et al., for example, reported lower counts of *Bifidobacterium* and lactobacilli in the gut microbiota of patients with MDD compared with healthy controls [9], results supported by a number of previous studies in animal models [10–12]. *Bifidobacterium* and lactobacilli are commonly used as probiotics, which are gaining attention for their ability to maintain human physiological homeostasis in the gut environment and immune system, as well as psychological homeostasis to reduce the risk of developing depression [13].

This paper reviews recent findings on the possible mechanisms underlying the onset of MDD that can be modulated by the gut microbiome via the gut–brain axis, and discusses candidate interventions that may modulate the pathophysiology of depression, with a focus on the use of probiotics including lactobacilli, bifidobacteria, and butyrate-producing bacteria.

2. Pathogenesis of Depression Related to the MGB Axis

In this section, we describe possible mechanisms underlying the onset of MDD that can be mediated by the gut–brain axis, focusing on an abnormal stress response, decreased neurogenesis, and neural inflammation; and consider the possible involvement of the gut microbiome in such mechanisms.

2.1. Abnormal Stress Response

It has long been noted that life situations involving chronic stress increase the risk for MDD onset. The HPA axis is well recognized as a key pathway of stress response in mammals. Stress stimulus promotes the release of hypothalamic corticotropin-releasing hormone (CRH), and CRH induces the release of adrenocorticotropic hormone (ACTH) from the pituitary gland. ACTH is, in turn, secreted into blood circulation to stimulate glucocorticoid (e.g., cortisol in humans and corticosterone in rodents) secretion from the adrenal cortex. In addition to their effects on metabolism and the immune system, glucocorticoids regulate their own secretion by suppressing CRH secretion and HPA axis activation, which is known as negative feedback. It has been suggested that negative feedback of this kind is impaired in MDD patients. Carroll et al. conducted a dexamethasone (DEX; a type of glucocorticoid) test on melancholic MDD patients, and showed elevated plasma cortisol levels in the patients [14], while a later-developed method (DEX/CRH test) demonstrated that negative feedback was impaired in the patients [15]. As a result, blood cortisol levels are continuously high in MDD patients, and brain exposure to high levels of cortisol induces inflammation and reduction in BDNF levels, which are thought to underlie the pathophysiology of MDD [16]. Recently, cumulative HPA axis activities have been assessed based on hair cortisol levels, and the results suggest that stress and depressive symptoms are related to high cortisol levels [17,18]. Furthermore, in stress-induced depression model animals, the blood corticosterone concentration increased, and the brain BDNF level decreased, with resulting inflammation in the hippocampus and prefrontal cortex [19–21], while chronic administration of corticosterone to rodents induced a similar pathogenesis [22,23].
results suggest that HPA axis-mediated dysregulation of stress response (i.e., HPA axis hyper-activation) contributes to the development and progress of depressive symptoms.

Accumulating evidence suggests an involvement of the MGB axis in the modulation of the host’s stress response. In Sudo et al.’s landmark study, germ-free mice showed an enhanced secretion of plasma ACTH and corticosterone, when compared with specific-pathogen-free (SPF) mice, under restraint stress [10], and it was later shown that modulation of the gut microbiota could affect the stress response, including the HPA axis [24,25]. Meanwhile, numerous studies, both animal and human, have been performed on the role of probiotics in stress resilience [26–30]. It has been shown that oral administration of *Lactobacillus paracasei* strain Shirota (LcS; basonym, *Lactobacillus casei* strain Shirota) provoked activity of the gastric branch of the vagal afferent to suppress the stress-induced increase in blood corticosterone and the activation of CRH-positive neurons in the paraventricular nucleus of the hypothalamus in rats exposed to water-avoidance stress [31]. In human trials on healthy medical students under academic examination stress, this probiotic strain suppressed the stress-related increase of salivary cortisol and the onset of physical symptoms [31]. These results suggest that the sensory information on the gut microenvironment, including probiotics administration, is transmitted to the brain via vagal afferents, resulting in modulation of the stress response.

2.2. Decreased Neurogenesis and Its Association with BDNF

The hippocampus is a unique structure in which neurogenesis is maintained throughout life. Several animal studies suggested that decreased neurogenesis in the hippocampus resulted in a reduction in its volume, and BDNF was involved in these changes [32,33]. BDNF, which is produced by nerve cells, microglia, and astrocytes in broad regions of the brain, plays an important role in the survival, maintenance, differentiation, and synaptic plasticity of nerve cells. Measures of blood and plasma BDNF levels are considered to reflect brain-tissue BDNF levels [34], and decreased serum BDNF levels have been observed in MDD patients [35,36]. Structural imaging studies have shown that serum BDNF levels correlate with hippocampal volume, with lesser volume being observed in MDD patients than in healthy controls [37,38]. Furthermore, an animal study demonstrated that the administration of SSRIs increased hippocampal BDNF levels and neurogenesis, accompanied by a reduction in depressive behavior [39], a result confirmed in a human study, where antidepressant treatment recovered decreased levels of serum BDNF in MDD patients, along with improvement in related symptoms [40,41]. Santarelli et al. investigated the effect of the chronic SSRI, fluoxetine, on mice with neurogenesis suppressed by X-irradiation, and found that the mice were insensitive to behavioral effects of fluoxetine, indicating that the effects of chronic SSRIs may be mediated by the stimulation of neurogenesis in the hippocampus [42]. These results suggest that a reduction in BDNF impairs neurogenesis, resulting in MDD onset, and that antidepressants could exert a beneficial effect on MDD symptoms by recovering the brain BDNF level.

Several factors are known to affect the BDNF level, including exposure to excessive stress, inflammation, and aging. In addition to these factors, the gut microbiome has been reported to play an important role in controlling the BDNF level of the host. Since Sudo et al. showed that hippocampal BDNF levels decreased in germ-free mice compared with SPF mice [10], the relationship between BDNF and the gut microbiota has been investigated in numerous studies, using germ-free, antibiotic-treated, depression model, and fecal microbiota-transplanted mice [43–47], while impaired hippocampal neurogenesis has been reported in germ-free mice [48]. As an increase in the BDNF level correlates with an improvement in depressive symptoms [35,36], modulation of the gut microbiome, to increase the brain BDNF level and neurogenesis, may lead to an improvement in the symptoms. Gut microbiota-derived metabolites, especially short-chain fatty acids, have been confirmed to be key molecular mediators in the MGB axis, and butyrate is one of the bacteria-derived candidates that can link the gut microbiota with brain BDNF regulation. After absorption at the colon, butyrate is utilized by colonocyte for energy
production, some of which then travels through the systemic circulation and reaches the brain through the blood–brain barrier [49–51]. In animal studies, butyrate was shown to accelerate BDNF expression in the hippocampus via inhibition of histone deacetylase [52], and to improve depressive behavior in stress-induced depression model mice [53]. As previously mentioned, several studies have revealed a lower level of butyrate-producing bacteria in the gut microbiota of MDD patients, and butyrate-producing Faecalibacterium and Coprococcus bacteria were positively associated with higher quality of life indicators in a cohort study of the Flemish Gut Flora Project [54]. These results consistently indicate that the pathophysiology of MDD could be modulated by gut microbiota-derived butyrate through the maintenance of BDNF expression.

2.3. Neuroinflammation

The last decade or so has seen a focus on the involvement of inflammation (neuroinflammation and systemic inflammation) in depressive symptoms, and increased levels of inflammatory markers have been observed in MDD patients. A meta-analysis conducted by Wang and Miller indicated higher levels of IL-6 and IL-8 in the cerebrospinal fluid (CSF) of MDD patients, while Goldsmith et al. observed higher levels of IL-6 and TNF-α in the blood of such patients [55,56]. It has also been shown that peripheral blood C-reactive protein (CRP) is elevated in patients with MDD, and more so in treatment-resistant patients [57]. Plasma CRP is proposed as a peripheral biomarker that reflects peripheral and central inflammation. Furthermore, Felger et al. have shown that plasma CRP strongly correlates with CSF CRP, and associates with CSF inflammatory markers related to depressive symptom severity [58]. In terms of neuroinflammation, it is known that microglia play a pivotal role in the production of inflammatory cytokines, and Nie et al. showed that repeated social defeat stress induced activation of microglia via the Toll-like receptor (TLR)-2 and TLR-4, up-regulation of IL-1α and TNF-α, and increased social avoidance and anxiety [59]. It is also known that microglia are involved in the pathogenesis of MDD induced by peripheral LPS-associated inflammation. Weng et al. reported that there was an increased number of microglia in the prefrontal cortex of mice intraperitoneally injected with E. coli derived-LPS, which was accompanied by an increase in depressive behavior [60]. They also found up-regulation of CD11b, IL-1β, IL-6, and TNF-α gene expression in the prefrontal cortex of the mice, and the changes were suppressed by SSRI. It has also been shown that astrocytes are involved in the pathogenesis of stress- and LPS-induced inflammation, accompanied by depressive symptoms [61,62].

Some hypotheses relate inflammation to the pathogenesis of MDD. One focuses on alteration of the tryptophan metabolic pathway. It is known that tryptophan is metabolized to both serotonin and kynurenine, with kynurenine being further metabolized to quinolinic acid, which has neurotoxicity. It has been reported that the tryptophan metabolic pathway to kynurenine and quinolinic acid is activated in MDD patients [63,64], and that IFN-γ up-regulates the kynurenine pathway while the serotonin pathway is down-regulated [65]. These results suggest that neuroinflammation causes the metabolic pathway shift from tryptophan toward kynurenine, and that quinolinic acid impairs the neurons, inducing depressive symptoms. Another hypothesis focuses on a dysfunction of the HPA axis and neurogenesis. An activated glucocorticoid receptor (GR) inhibits the expression and function of inflammatory cytokine, whereas IL-1α suppresses GR activation to induce glucocorticoid resistance (i.e., a reduced sensitivity to glucocorticoid) [66]. IL-1, IL-6, and TNF-α have been shown to stimulate the HPA axis and induce the release of glucocorticoid [67]. Thus, inflammation causes both glucocorticoid resistance and HPA axis activation, resulting in hyper-activation of the HPA axis. Several reports have suggested another pathway, in which systemic administration of IFN-α or IL-1β down-regulates BDNF expression, suppressing neurogenesis in the hippocampus, though the precise mechanism remains unclear [68,69].

Before the MGB axis gained research attention, extensive research sought to elucidate the relationship between the gut microbiota and inflammation and immune response,
and numerous studies have shown that the gut microbiota directly affects the balance between pro- and anti-inflammatory responses in the gut [70–73]. Butyrate is also known to exert anti-inflammatory effects on immune cells. It has been shown that butyrate inhibits the activation of NF-κB and production of inflammatory cytokines in peripheral blood mononuclear cells, as well as the production of TNF-α in neutrophils [74,75], while Furusawa et al. showed that butyrate induced differentiation of the T-regulatory cells to ameliorate colitis [76]. Regarding the function of butyrate in brain regions, a recent study showed that butyrate supplementation improved behavioral abnormalities and modulated microglial homeostasis in high-fat diet-fed mice [77]. In terms of the relationship between MDD and inflammation, intestinal mucosal barrier function has been suggested to be involved in MDD onset. Intestinal luminal antigens/toxins such as LPS cause systemic inflammation and depressive symptoms when they translocate into blood circulation [60]. LPS and inflammatory cytokines also induce blood–brain barrier dysfunction [78–80]. Thus, it is suggested that intestinal barrier dysfunction causes an influx of intraluminal antigens/toxins, inflammatory cytokines, T-cells, and macrophages to the brain, inducing neuroinflammation via activation of microglia and astrocytes. This claim is supported by the observation that intestinal barrier dysfunction was accompanied by inflammation in MDD patients, and the degree of dysfunction correlated with the severity of the MDD symptoms [81]. An impairment of the intestinal barrier function is suggested to be a consequence of stress, inflammation, and gut dysbiosis; and these factors are thought to interact with each other to exacerbate the impairment.

2.4. Other MDD-Related Factors

In this section, we discuss other MDD-related factors, such as sleep disorders, metabolic disorders, and neurotransmitter dysregulation, which are considered to be closely associated with MDD pathophysiology, though the involvement of the gut microbiome is less certain in this respect.

2.4.1. Sleep Disorders

Sleep disorders are associated with psychiatric disorders (including MDD), and are recognized as a risk factor for their development [82]. A meta-analysis conducted by Zhai et al. indicated that both short and long sleep duration were significantly associated with an increased risk of MDD in adults [83]. Recently, Liu et al. showed that insomnia mediated the association between perceived stress and depression but did not affect perceived stress directly [84]. These results suggest that insomnia could be a medical condition on its own, rather than a symptom of depression, and that improving sleep conditions could attenuate or prevent stress-induced depressive symptoms. It has been shown that the gut microbiome can affect sleep conditions. Ogawa et al., for example, showed that gut microbiota depletion due to antibiotic treatment resulted in an altered sleep/wake architecture, with changes in the intestinal balance of neurotransmitters [85]. Furthermore, a human study based on electroencephalogram activity revealed that probiotic treatment improved sleep conditions [86,87]. The hypothalamus is a potential target of the gut–brain axis, because gut hormones are involved in appetite regulation in the hypothalamus, and some probiotics are known to affect neuronal activity in there [31]. The hypothalamus works as a key center for regulating the sleep-wake cycle, and is also the region where the HPA axis initiates a series of reactions for the maintenance of homeostasis. Given such functional associations, it is reasonable to suppose that the gut microbiota or its metabolites influence the brain functions, via enteroenocrine cells or afferent neurons, to improve sleep conditions and thereby modulate depressive symptoms.

2.4.2. Metabolic Disorders

MDD patients often have metabolic disorders, and patients with metabolic disorders also tend to have depressive symptoms [88–90]. In recent years, it has been noted that systemic chronic inflammation is associated with intestinal mucosal barrier dysfunction,
and partly involved in the development of obesity and type 2 diabetes [90,91]. As discussed in Section 2.3, systemic inflammation is considered a pathogenesis of MDD, hence metabolic diseases and MDD may share pathological mechanism commonalities. Elevated levels of the gut hormones ghrelin and leptin have also been reported in MDD patients [92,93]. These hormones, secreted from gastric endocrine cells and adipocytes, respectively, function in appetite regulation. It has become clear that the hormones are also involved in sleep, cognition, the reward system, and stress response (HPA axis activity), influencing brain functions from the digestive tract [94–99]. However, the significance of their effects on brain functions remains to be determined, because there is conflicting evidence regarding their activity. Some studies suggest that ghrelin and leptin enhance HPA axis activity, but the opposite effect has also been reported [97,99–102]. In MDD patients who are comorbid with metabolic disorder, manipulating the gut microbiota may have beneficial effects on depressive symptoms through the modulation of these hormones.

2.4.3. Dysregulation of Monoamines and Gamma-Aminobutyric Acid

Monoamines are known to be involved in mood, emotion, arousal, appetite, motivation, anxiety, and the reward system [103–110]; additionally, dysfunction in the monoamine nervous system may be involved in depressive symptoms such as increased anxiety, decreased motivation, and anhedonia. Lesser levels of gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter, have been observed in the brains of MDD patients [111]. Mann et al. reported that the GABA level in CSF was lower in MDD patients compared with healthy controls, and the lower level was correlated with increasing severity of anxiety in the patients [112]. GABA neurons are broadly present in the brain, and participate in many functions, including anxiety, motivation, and the reward system [113–115], as well as playing an important role in ameliorating MDD symptoms [116].

It is well-known that more than 90% of serotonin is present in the enterochromaffin cells located in the gastrointestinal tract, and is released in response to stimuli from the gut lumen, to regulate gut motility and perception. Gut microbiota-derived metabolites or components induce the synthesis and release of serotonin [117–119], and increased serotonin synthesis in the gastrointestinal tract may cause decreased levels of tryptophan in blood circulation, with a resulting reduction in brain serotonin synthesis. Furthermore, monoamine levels in lumen were shown to be significantly lower in germ-free mice compared to SPF-microbiota transplanted mice [120,121]. Some bacteria are known to produce monoamine [122], and several strains of lactic acid bacteria have been identified as having the ability to produce GABA [123]. The significance and role of these gut microbiota-derived neuroactive metabolites are largely unknown, but given their function, they may play a pivotal role in the MGB axis. For example, if they are absorbed in the gut (or enter due to intestinal-barrier dysfunction), they can activate sensory nerves in peripheral and enteral nerve or endocrine cells, and thereby transmit stimulation to the brain. There is, as of yet, insufficient evidence to determine the relation between neuroactive metabolites from the gut microbiota and neurotransmitters in the host brain; further investigation is required.

3. Proposals for Improving the Pathophysiology of MDD via the MGB Axis

Several studies have shown that depressive symptoms improved in patients with irritable bowel syndrome (IBS), when treated with FMT [124,125]. FMT is considered to restore or reconstruct the gut microbiota, and thus contribute to the amelioration of gastrointestinal and neuropsychiatric symptoms, although confounding in bidirectional associations between IBS and MDD must be considered. In addition to the structural modulation of the gut microbiota, a therapeutic approach focusing on the characteristics of specific bacteria is now applied to psychiatric diseases, including MDD. The following sections outline the therapeutic potential of probiotics, including butyrate-producing bacteria, to ameliorate the pathophysiology of MDD via the MGB axis (Figure 1).
3.1. Ameliorating the Stress Response

Several human trials have demonstrated the function of probiotics in controlling anxiety and depression. Probiotics that confer such benefits are now called psychobiotics, which have been defined as “a live organism that, when ingested in adequate amounts, produces a health benefit in patients suffering from psychiatric illness” [126]. Mohammadi et al. demonstrated that the administration of probiotic yoghurt or capsules containing *Lactobacillus acidophilus* LA5 and *Bifidobacterium lactis* BB12 for six weeks improved mental health parameters of petrochemical workers, as measured by the General Health Questionnaire (GHQ) and the Depression Anxiety and Stress Scale (DASS) [127]. Pinto-Sanchez et al. investigated the effects of probiotic powder containing *Bifidobacterium longum* NCC3001 on anxiety and depression in patients with IBS [128], and found that more patients provided with probiotic powder showed a reduction in depression scores compared to those given the placebo, while a functional magnetic resonance imaging analysis showed that responses to negative emotional stimuli in multiple regions of the brain were more reduced in the probiotic than in the placebo group. Benton et al. conducted a randomized controlled trial in healthy subjects consisting mainly of older adults, to examine the effects of LcS on mood and cognitive function [129]. In a subgroup with a high depressive index at baseline, intervention subjects showed a significant improvement in depressive mood compared with subjects who received a placebo control. These results were supported by those from an open trial using the same probiotic strain in patients with MDD or bipolar disorder [130]. There, it was demonstrated that depressive symptoms and sleep quality were improved.
after LcS treatment, and the effect was associated with the gut microbiota composition, namely, abundance of Actinobacteria, including Bifidobacterium.

Recent findings indicate that some probiotic strains can ameliorate stress-induced physiological changes as well. LcS, for example, suppressed stress-induced increases in glucocorticoid levels in both a human academic stress model (salivary cortisol) and a rat water-avoidance stress model (plasma corticosterone) [31]. In a similar study using a human academic stress model, heat-killed Lactobacillus gasseri CP2305 ameliorated chronic-stress-associated responses, including increased salivary cortisol levels and increased expression of stress-responsive microRNAs [131]. These actions might be mediated by direct neural communication between the gut and brain. Intraduodenal injection of Lactobacillus johnsonii La1 activated the gastric vagal afferents and inhibited renal sympathetic nerve activity [132]. LcS has shown similar results [31], and its effect on CRH-induced sympathetic activation is suppressed by vagotomy [133]. Finally, the administration of Levilactobacillus brevis SBC8803 (basonym, Lactobacillus brevis SBC8803) promotes the secretion of serotonin from the small intestine of mice [134], which may induce an activation of the intestinal branch of the vagal afferent. These results suggest that some probiotic strains modulate stress-induced activation of the HPA axis, and the subsequent onset of depression, by acting on the neuroendocrine system.

3.2. Maintenance of BDNF Expression and Neurogenesis

Given that impaired neurogenesis accompanied by BDNF reduction is involved in the pathophysiology of MDD, the recovery of BDNF expression is considered to be a promising therapeutic approach for the maintenance of neurogenesis. Animal studies using a chronic stress model demonstrated that administration of butyrate-producing bacteria (Clostridium butyricum or Faecalibacterium prausnitzii) attenuated depressive behavior, with an increase in BDNF levels [135,136]. In a prospective open-label trial by Miyaoka et al., C. butyricum MIYAIRI 588 was effective against depressive symptoms in antidepressant-resistant MDD patients, when used in combination with antidepressants [137]. Although further studies, using a larger, double-blind, parallel-group design, are required to confirm these findings, the use of butyrate-producing bacteria will attract increasing attention as a promising therapeutic approach for depression. The supplementation of lactic acid bacteria or bifidobacteria offers an alternative means to up-regulate butyrate production by the gut microbiota, because these bacteria produce abundant amounts of lactate and/or acetate, which are then metabolized to butyrate by butyrate-producing bacteria [138]. In chronic stress-induced depressive mice, Bifidobacterium longum subsp. infantis E41 increased the BDNF level, with a resulting decrease in depressive behavior, but did not modulate the increased levels of serum corticosterone. Additionally, E41 increased the cecal butyrate concentration, which correlated with the BDNF level and depressive behavior [139]. There are also several other strains of lactic acid bacteria and bifidobacteria that were shown to improve depressive symptoms with an increase in butyrate [140,141].

Recently, Wei et al. investigated the effect of indole, a tryptophan metabolite of colonic microbiota, on hippocampal neurogenesis, and showed that the neurogenic effect was mediated by the aryl hydrocarbon receptor (AhR) [142]. In that study, however, another AhR ligand, kynurenine, did not induce neurogenesis, suggesting ligand specificity in the AhR-mediated regulation of neurogenesis. It is known that indole is further metabolized to indoxyl sulfate, and the latter is involved in the onset and exacerbation of chronic kidney disease [143], so the use of indole and indole-producing bacteria must be carefully evaluated for its safety.

3.3. Anti-Inflammatory Effect

Butyrate-producing bacteria are thought to exert beneficial effects on depressive symptoms in terms of their anti-inflammatory function. In an animal study, administration of F. prausnitzii to trinitrobenzene sulphonic acid-induced colitis mice reduced the severity of colitis, with increasing IL-10 secretion and decreasing TNF-α and IL-12 secretion in
the colon [144]. There are still few human-study results concerning the effect of butyrate-producing bacteria on inflammatory diseases, but a meta-analysis revealed a negative association between the abundance of *F. prausnitzii* and IBD activity [145].

Purton et al. conducted a systematic review and meta-analysis of the effect of probiotics on the tryptophan-kynurenine pathway, which indicated that probiotics can modulate the serum kynurenine level and kynurenine/tryptophan ratio [146]. Further, *Lactiplantibacillus plantarum* 299v (basonym, *Lactobacillus plantarum* 299v) reduced the kynurenine concentration in the plasma of MDD patients, along with improvement in cognitive function, though the depressive symptoms were not improved [147]; and administration of *Lactobacillus helveticus* R0052 and *Bifidobacterium longum* R0175 improved depressive symptoms and reduced the kynurenine/tryptophan ratio [148]. Further studies are needed to elucidate what kind of molecules in the kynurenine metabolic pathway are involved in depressive symptoms, and how such molecules affect the symptoms.

Tightening the intestinal mucosal barrier also plays an important role in suppressing systemic inflammation and consequent neuroinflammation. Numerous results suggest that the gut microbiome modulate the intestinal barrier function [149–151]. In this context, butyrate has been shown to enhance the intestinal barrier function through maintenance of the expression of tight junction proteins including claudins, occludin, and zonula occludens protein-1 (ZO-1) [152], and an animal study has demonstrated that oral administration of *C. butyricum* or butyrate reduces intestinal injury associated with severe acute pancreatitis [153]. Some probiotics are reported to ameliorate intestinal barrier dysfunction via different mechanisms. Ait-Belgnaoui et al. showed that *Lactobacillus farciminis* administration prevented a stress-induced increase in colonic paracellular permeability, by inhibiting myosin light chain phosphorylation, which induces epithelial cell cytoskeleton contraction [154]. Another probiotic strain, *Lactobacillus rhamnosus* GG (LGG), prevented the hydrogen peroxide-induced disruption of barrier function, by maintaining the expression and localization of occludin and ZO-1, which form the tight junctions between epithelial cells [155]. Furthermore, a human study showed that ingestion of LGG reduced the gastric hyper-permeability induced by indometacin [156], while, in another human study, *Lactiplantibacillus plantarum* strain WCFS1 (basonym, *Lactobacillus plantarum* strain WCFS1) up-regulated the duodenal expression of occludin and ZO-1, and in vitro experiments suggested that this effect was mediated by TLR-2 [157]. Overall, these results suggest that butyrate-producing bacteria and some probiotics can ameliorate depressive symptoms through restoration of intestinal barrier dysfunction. Additionally, it has been shown that the probiotic bifidobacterial strains improve colonic permeability in obese adults when administered with prebiotics, galacto-oligosaccharides [158], and the results allow us to suppose that the symbiotic combinations of probiotics and prebiotics are also effective to comorbid depressive symptoms in metabolic disorders.

4. Future Perspectives

The gut microbiota, as well as its dysbiosis, both closely related to brain function via the MGB axis, are involved in the pathogenesis of MDD. Though many issues remain to be addressed before the numerous mechanisms involved are fully understood, accumulating evidence suggests that gut dysbiosis induces an excessive stress response, and major bacterial metabolites, specifically butyrate, affects BDNF expression in the brain. This review has mainly focused on the mechanisms underlying the effect of microbes on depression, but it is also important to understand how microbes are affected by changes in the host’s psychological and physiological state. A very recent study showed that exposure to chronic stress reduced the secretion of α-defensins, effector peptides of innate enteric immunity produced by Paneth cells in the small intestine, which resulted in gut dysbiosis and an impairment of intestinal metabolite homeostasis [159]. To extrapolate the mechanisms revealed in animal studies to therapeutic effects in humans, it would be necessary to gain a deeper understanding of the bidirectional communication between the gut microbiota and brain.
It is becoming clear that abnormal stress response, reduced neurogenesis and BDNF expression, and neuroinflammation are involved in the pathogenesis of MDD. BDNF is thought to also be associated with a variety of other psychiatric disorders [160]. Hippocampal neurogenesis steadily decreases with aging, but drops sharply in patients with Alzheimer’s disease (AD) [161]. Neuroinflammation is also recognized as one of the potential mechanisms mediating neurodegenerative disorders, including AD [162]. Clarifying the relationship between the pathogenesis of MDD and the gut microbiome would also lead to better understanding of other neuropsychiatric disorders.

Probiotics, the gut microbiota, and their metabolites, especially SCFAs such as butyrate, play an important role in maintaining host homeostasis. Some probiotic strains induce excitation of the vagal afferents (with the stimulus then transmitted to the brain), and suppress stress-associated neural activation. It is expected that the means by which host cellular sensors detect bacterial components and induce signal transduction will be further elucidated, enabling identification of the bacterial components that act on the host cells, and determination of the specific mechanisms involved in their activity. To understand the dynamics of bacterial metabolites in the human body is another important issue, and a further challenge lies in determining whether butyrate reaches the brain via the blood stream, to directly influence the brain functions, or if another, peripheral tissue acts as an intermediate. Through these efforts, future research is expected to further clarify the underlying mechanisms of the pathogenesis of MDD, and lead to the development of promising microbiome-based therapeutics.

Author Contributions: K.S. and K.M. were responsible for the conceptualization and the writing: original draft preparation, review, and editing. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Acknowledgments: We thank Mitsuhisa Kawai, of the Yakult Central Institute, for his valuable advice regarding the drafting of the manuscript.

Conflicts of Interest: K.S. and K.M. are employees of Yakult Honsha Co., Ltd., Tokyo, Japan.

References
1. World Health Organization. Available online: https://www.who.int/en/news-room/fact-sheets/detail/depression (accessed on 3 December 2021).
2. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018, 392, 1789–1858. [CrossRef]
3. Owens, M.J. Selectivity of antidepressants: From the monoamine hypothesis of depression to the SSRI revolution and beyond. J. Clin. Psychiatry 2004, 65, 5–10.
4. Boku, S.; Nakagawa, S.; Toda, H.; Hishimoto, A. Neural basis of major depressive disorder: Beyond monoamine hypothesis. Psychiatry Clin. Neurosci. 2018, 72, 3–12. [CrossRef]
5. Cryan, J.F.; O’Mahony, S.M. The microbiome-gut-brain axis: From bowel to behavior. Neurogastroenterol. Motil. 2011, 23, 187–192. [CrossRef] [PubMed]
6. Zheng, P.; Zeng, B.; Zhou, C.; Liu, M.; Fang, Z.; Xu, X.; Zeng, L.; Chen, J.; Fan, S.; Du, X.; et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host’s metabolism. Mol. Psychiatry 2016, 21, 786–796. [CrossRef] [PubMed]
7. Liu, Y.; Wang, H.; Gui, S.; Zeng, B.; Pu, J.; Zheng, P.; Zeng, L.; Luo, Y.; Wu, Y.; Zhou, C.; et al. Proteomics analysis of the gut–brain axis in a gut microbiota-dysbiosis model of depression. Transl. Psychiatry 2021, 11, 568. [CrossRef] [PubMed]
8. Knudsen, J.K.; Bundgaard-Nielsen, C.; Herrild, S.; Nielsen, R.E.; Leutscher, P.; Sørensen, S. Gut microbiota variations in patients diagnosed with major depressive disorder-A systematic review. Brain Behav. 2021, 11, e02177. [CrossRef] [PubMed]
9. Aizawa, E.; Tsuji, H.; Asahara, T.; Takahashi, T.; Teraishi, T.; Yoshida, S.; Ota, M.; Koga, N.; Hattori, K.; Kunugi, H. Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder. J. Affect. Disord. 2016, 202, 254–257. [CrossRef] [PubMed]
10. Sudo, N.; Chida, Y.; Aiba, Y.; Sonoda, J.; Oyama, N.; Yu, X.-N.; Kubo, C.; Koga, Y. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J. Physiol. 2004, 558, 263–275. [CrossRef]
11. Marin, I.A.; Goertz, J.E.; Ren, T.; Rich, S.S.; Onengut-Gumuscu, S.; Farber, E.; Wu, M.; Overall, C.C.; Kipnis, J.; Gaultier, A. Microbiota alteration is associated with the development of stress-induced despair behavior. *Sci. Rep.* 2017, 7, 43859. [CrossRef]
12. Chevalier, G.; Siopi, E.; Guenin-Macé, L.; Pascal, M.; Laval, T.; Riflett, A.; Boneca, I.G.; Demangel, C.; Colsch, B.; Pruvost, A.; et al. Effect of gut microbiota on depressive-like behaviors in mice is mediated by the endocannabinoid system. *Nat. Commun.* 2020, 11, 6363. [CrossRef]
13. Hori, T.; Matsuda, K.; Oishi, K. Probiotics: A dietary factor to modulate the gut microbiome, host immune system, and gut-brain interaction. *Microorganisms* 2020, 8, 1401. [CrossRef] [PubMed]
14. Carroll, B.J.; Feinberg, M.; Greden, J.F.; Tarika, J.; Albala, A.A.; Haskett, R.F.; James, N.M.; Kronfol, Z.; Lohr, N.; Steiner, M.; et al. A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. *Arch. Gen. Psychiatry* 1981, 38, 15–22. [CrossRef]
15. Heuser, I.; Yassouridis, A.; Holsboer, F. The combined dexamethasone/CRH test: A refined laboratory test for psychiatric disorders. *J. Psychiatr. Res.* 1994, 28, 341–356. [CrossRef]
16. Wrobel, A.; Sereiko, A.; Rechberger, E.; Banczerowska-Göriska, M.; Poleszak, E.; Dudka, J.; Skorupska, K.; Miotla, P.; Semczuk, A.; Kulik-Rechberger, B.; et al. Inhibition of Rho kinase by GSK 269662 reverses both corticosterone-induced detrusor overactivity and depressive-like behaviour in rats. *Eur. J. Pharmacol.* 2018, 837, 127–136. [CrossRef]
17. Wu, Y.; Li, S.; Hu, K.; Yang, J. Evidence of the moderating role of hair cortisol and hair cortisone in the relationship between work stress and depression symptoms among Chinese fishermen. *J. Affect. Disord.* 2021, 294, 868–875. [CrossRef] [PubMed]
18. Green, C.; Soliçyn, A.; Harris, M.A.; Shen, X.; Romaníuk, L.; Barbu, M.C.; Hawkins, E.L.; Wardlaw, J.M.; Steele, J.D.; Waiter, G.D.; et al. Hair glucocorticoids are associated with childhood adversity, depressive-like symptoms and reduced global and lobar grey matter in generation Scotland. *Transl. Psychiatry* 2011, 11, 523. [CrossRef]
19. Gu, F.; Wu, Y.; Liu, Y.; Dou, M.; Jiang, Y.; Liang, H. *Lactobacillus casei* improves depression-like behavior in chronic unpredictable mild stress-induced rats by the BDNF-TrkB signal pathway and the intestinal microbiota. *Food Funct.* 2020, 11, 6148–6157. [CrossRef]
20. Huang, P.; Gao, T.; Dong, Z.; Zhou, C.; Lai, C.; Yan, T.; Liu, Y.; Zhao, X.; Sun, X.; Hua, H.; et al. Neural circuitry among connecting the hippocampus, prefrontal cortex and basolateral amygdala in a mouse depression model: Associations correlations between BDNF levels and BOLD—fMRI signals. *Brain Res. Bull.* 2018, 142, 107–115. [CrossRef]
21. Chen, F.; Chen, S.; Liu, J.; Amin, N.; Jin, W.; Fang, M. Agomelatine softens depressive-like behavior through the regulation of autophagy and apoptosis. *Biomed. Res. Int.* 2021, 2021, 6664591. [CrossRef] [PubMed]
22. Song, L.; Wu, X.; Wang, J.; Guan, Y.; Zhang, Y.; Gong, M.; Wang, Y.; Li, B. Antidepressant effect of catalpol on corticosterone-induced depressive-like behavior involves the inhibition of HPA axis hyperactivity, central inflammation and oxidative damage probably via dual regulation of NF-κB and Nrf2. *Brain Res. Bull.* 2021, 177, 81–91. [CrossRef]
23. De Castro Chaves, R.; Mallmann, A.S.V.; Oliveira, N.F.; Oliveira, I.C.M.; Capibaribe, V.C.C.; da Silva, D.M.A.; Lopes, I.S.; Valentim, J.T.; de Carvalho, A.M.R.; Macêdo, D.S.; et al. Reversal effect of Riparin IV in depression and anxiety caused by corticosterone chronic administration in mice. *Pharmacol. Biochem. Behav.* 2019, 180, 44–51. [CrossRef]
24. Wu, Q.; Xu, Z.; Song, S.; Zhang, H.; Zhang, W.; Liu, L.; Chen, Y.; Sun, J. Gut microbiota modulates stress-induced hypertension via the HPA axis. *Brain Res. Bull.* 2020, 162, 49–58. [CrossRef]
25. Wu, W.-L.; Adame, M.D.; Liou, C.-W.; Barlow, J.T.; Lai, T.-T.; Sharon, G.; Schretter, C.E.; Needham, B.D.; Wang, M.I.; Tang, W.; et al. Microbiota regulate social behaviour via stress response neurons in the brain. *Nature* 2021, 595, 409–414. [CrossRef] [PubMed]
26. Stenman, L.K.; Patterson, E.; Meunier, J.; Romaníuk, L.; Meunier, J.; Lehtinen, M.J. Strain specific stress-modulating effects of candidate probiotics: A systematic screening in a mouse model of chronic restraint stress. *Behav. Brain Res.* 2020, 379, 112376. [CrossRef]
27. Tian, P.; O’Riordan, K.J.; Lee, Y.K.; Wang, G.; Zhao, H.; Cryan, J.F.; Chen, W. Towards a psychobiotic therapy for depression: *Bifidobacterium breve* CCFM1025 reverses chronic stress-induced depressive symptoms and gut microbial abnormalities in mice. *Neurobiol. Stress* 2020, 12, 100216. [CrossRef] [PubMed]
28. Venkataraman, R.; Madempudi, R.S.; Neelamraju, J.; Ahire, J.J.; Vinay, H.R.; Lal, A.; Thomas, G.; Stephen, S. Effect of multi-strain probiotic formulation on students facing examination stress: A double-blind, placebo-controlled study. *Probiotics Antimicrob. Proteins* 2021, 13, 12–18. [CrossRef]
29. Lew, L.C.; Hor, Y.Y.; Yusoff, N.A.A.; Choi, S.B.; Yusoff, M.S.B.; Roslan, N.S.; Ahmad, A.; Mohammad, J.A.M.; Abdullah, M.F.I.L.; Zakaria, N.; et al. Probiotic *Lactobacillus plantarum* P8 alleviated stress and anxiety while enhancing memory and cognition in stressed adults: A randomised, double-blind, placebo-controlled study. *Clin. Nutr.* 2019, 38, 2053–2064. [CrossRef]
30. Quero, C.D.; Manonelles, P.; Fernández, M.; Abellán-Aynés, O.; López-Plaza, D.; Andreu-Caravaca, L.; Hinchado, M.D.; Gálvez, I.; Ortega, E. Differential health effects on inflammatory, immunological and stress parameters in professional soccer players and sedentary individuals after consuming a symbiotic. A triple-blinded, randomized, placebo-controlled pilot study. *Nutrients* 2021, 13, 1321. [CrossRef]
31. Takada, M.; Nishida, K.; Kataoka-Kato, A.; Gondo, Y.; Ishikawa, H.; Suda, K.; Kawai, M.; Hoshi, R.; Watanabe, O.; Igarashi, T.; et al. Probiotic *Lactobacillus casei* strain Shirot a relieves stress-associated symptoms by modulating the gut-brain interaction in human and animal models. *Neurogastroenterol. Motil.* 2016, 28, 1027–1036. [CrossRef]
32. Lee, J.; Duan, W.; Mattson, M.P. Evidence that brain-derived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice. *J. Neurochem.* 2002, 82, 1367–1375. [CrossRef] [PubMed]
33. Agrimi, J.; Spalletti, C.; Baroni, C.; Keceli, G.; Zhu, G.; Caragnano, A.; Matteucci, M.; Chelko, S.; Ramirez-Corra, G.A.; Bedja, D.; et al. Obese mice exposed to psychosocial stress display cardiac and hippocampal dysfunction associated with local brain-derived neurotrophic factor depletion. *BiolMedicine* 2019, 47, 384–401. [CrossRef] [PubMed]

34. Klein, A.B.; Williamson, R.; Santini, M.A.; Clemmensen, C.; Ettrup, A.; Rios, M.; Knudsen, G.M.; Aznar, S. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. *Int. J. Neuropsychopharmacol.* 2011, 14, 347–353. [CrossRef] [PubMed]

35. Karege, F.; Perret, G.; Bondolfi, G.; Schwall, M.; Bertschy, G.; Aubry, J.M. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. *Psychiatry Res.* 2002, 109, 143–148. [CrossRef]

36. Satomura, E.; Baba, H.; Nakano, Y.; Maeshima, H.; Suzuki, T.; Arai, H. Correlations between brain-derived neurotrophic factor and clinical symptoms in medicated patients with major depression. *J. Affect. Disord.* 2011, 135, 332–335. [CrossRef] [PubMed]

37. Frodl, T.; Meisenzahl, E.M.; Zill, P.; Baghai, T.; Rujescu, D.; Leinsinger, G.; Bottlender, R.; Schüle, C.; Zwanzger, P.; Engel, R.R.; et al. Reduced hippocampal volumes associated with the long variant of the serotonin transporter polymorphism in major depression. *Arch. Gen. Psychiatry* 2004, 61, 177–183. [CrossRef]

38. Bouckaert, F.; Dols, A.; Emsell, L.; de Winter, F.L.; Vansteelandt, K.; Claes, L.; Sunaert, S.; Stek, M.; Sienaat, P.; Vandenbulcke, M. Relationship between Hippocampal Volume, Serum BDNF, and depression severity following electroconvulsive therapy in late-life depression. *Neuropsychopharmacology* 2016, 41, 2741–2748. [CrossRef]

39. Ji, M.; Niu, S.; Mi, H.; Jang, P.; Li, Y.; Hu, W. Antidepressant functions of Jie Yu Chu Fan capsule in promoting hippocampal nerve cell neurogenesis in a mouse model of chronic unpredictable mild stress. *Ann. Transl. Med.* 2020, 8, 1020. [CrossRef]

40. Aydemir, O.; Devaci, A.; Taneli, F. The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: A preliminary study. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 2005, 29, 261–265. [CrossRef]

41. Shimizu, E.; Hashimoto, K.; Okamura, N.; Koike, K.; Komatsu, N.; Kumakiri, C.; Nakazato, M.; Watanabe, H.; Shinoda, N.; Okada, S.I.; et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. *Psychiatry* 2003, 54, 70–75. [CrossRef]

42. Santarelli, L.; Saxe, M.; Gross, C.; Surget, A.; Battaglia, F.; Dulawa, S.; Weissstaub, N.; Lee, J.; Duman, R.; Arancio, O.; et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. *Science* 2003, 301, 805–809. [CrossRef]

43. Clarke, G.; Grencham, S.; Scully, P.; Collins, J.; Jackson, W.; Lu, J.; Jury, J.; Deng, Y.; Blennerhassett, P.; MacRi, J.; McCoy, K.D.; et al. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. *Gastroenterology* 2011, 141, 599–609. [CrossRef]

44. Fröhlich, E.E.; Farzi, A.; Mayerhofer, R.; Reichmann, F.; Jaˇ can, A.; Wagner, B.; Zinser, E.; Bordag, N.; Magnes, C.; Fröhlich, E.; et al. Cognitive impairment by antibiotic-induced gut dysbiosis: Analysis of gut microbiota-brain communication. *Brain. Behav. Immun.* 2016, 56, 140–155. [CrossRef]

45. Ding, Y.; Bu, F.; Chen, T.; Shi, G.; Yuan, X.; Feng, Z.; Duan, Z.; Wang, R.; Zhang, S.; Wang, Q.; et al. Next-generation probiotic: *Akkermansia muciniphila* ameliorates chronic stress–induced depressive-like behavior in mice by regulating gut microbiota and metabolites. *Appl. Microbiol. Biotechnol.* 2015, 105, 8411–8426. [CrossRef]

46. Jang, H.M.; Kim, J.K.; Joo, M.K.; Shin, Y.J.; Lee, C.K.; Kim, H.J.; Kim, D.H. Transplantation of fecal microbiota from patients with inflammatory bowel disease and depression alters immune response and behavior in recipient mice. *Sci. Rep.* 2021, 11, 20406. [CrossRef]

47. Scott, G.A.; Terstege, D.J.; Yu, A.P.; Law, S.; Evans, A.; Epp, J.R. Disrupted neurogenesis in germ-free mice: Effects of age and sex. *Front. Cell Dev. Biol.* 2020, 8, 407. [CrossRef] [PubMed]

48. Cook, S.I.; Sellin, J.H. Review article: Short chain fatty acids in health and disease. *Aliment. Pharmacol. Ther.* 1998, 12, 499–507. [CrossRef]

49. Boets, E.; Gomand, S.V.; Deroover, L.; Preston, T.; Vermeulen, K.; de Preter, V.; van den Mooter, G.; de Vuyst, L.; Courtin, C.M.; et al. Systemic availability and metabolism of colonic-derived short-chain fatty acids in healthy subjects: A stable isotope study. *J. Physiol.* 2017, 595, 541–555. [CrossRef] [PubMed]

50. Sun, J.; Jing, Z.; Wang, F.; Chen, W.; Li, H.; Jin, J.; Zhang, H.; Pang, M.; Yu, J.; Liu, J. *Clostridium butyricum* pretreatment attenuates cerebral ischemia/reperfusion injury in mice via anti-oxidation and anti-apoptosis. *Neurosci. Lett.* 2016, 613, 30–35. [CrossRef]

51. Tu, F.; Pang, Q.; Huang, T.; Zhao, Y.; Liu, M.; Chen, X. Apigenin ameliorates post-stroke cognitive deficits in rats through histone acetylation–mediated neurochemical alterations. *Med. Sci. Monit.* 2017, 23, 4004–4013. [CrossRef]

52. Tian, P.; Zhu, H.; Qian, X.; Chen, Y.; Wang, Z.; Zhao, J.; Zhang, H.; Wang, G.; Chen, W. Consumption of butylated starch alleviates chronic restraint stress-induced neurobehavioral and gut barrier deficits through reshaping the gut microbiota. *Front. Immunol.* 2021, 12, 755481. [CrossRef] [PubMed]

53. Valles-Colomer, M.; Falony, G.; Darzi, Y.; Tigchelaar, E.F.; Wang, J.; Tito, R.Y.; Schieve, C.; Kurilshikov, A.; Joossens, M.; Wijmenga, C.; et al. The neuroactive potential of the human gut microbiota in quality of life and depression. *Nat. Microbiol.* 2019, 4, 623–632. [CrossRef] [PubMed]

54. Wang, A.K.; Miller, B.J. Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: Comparisons between schizophrenia, bipolar disorder, and depression. *Schizophr. Bull.* 2018, 44, 75–83. [CrossRef]
56. Goldsmith, D.R.; Rapaport, M.H.; Miller, B.J. A meta-analysis of blood cytokine network alterations in psychiatric patients: Comparisons between schizophrenia, bipolar disorder and depression. *Mol. Psychiatry* **2016**, *21*, 1696–1709. [CrossRef]

57. Chamberlain, S.R.; Cavanagh, J.; de Boer, F.; Mondelli, V.; Jones, D.N.C.; Drevets, W.C.; Cowen, P.J.; Harrison, N.A.; Pointon, L.; Pariente, C.M.; et al. Treatment-resistant depression and peripheral C-reactive protein. *Br. J. Psychiatry* **2019**, *214*, 11–19. [CrossRef] [PubMed]

58. Felger, J.C.; Haroon, E.; Patel, T.A.; Goldsmith, D.R.; Wommack, E.C.; Woolwine, B.J.; Le, N.-A.; Feinberg, R.; Tansey, M.G.; Miller, A.H. What does plasma CRP tell us about peripheral and central inflammation in depression? *Mol. Psychiatry* **2020**, *25*, 1301–1311. [CrossRef]

59. Nie, X.; Kitaoka, S.; Tanaka, K.; Segi-Nishida, E.; Imoto, Y.; Ogawa, A.; Nakano, F.; Tomohiro, A.; Nakayama, K.; Taniguchi, M.; et al. The innate immune receptors TLR2/4 mediate repeated social defeat stress-induced social avoidance through prefrontal microglial activation. *Neuron* **2018**, *99*, 464–479. [CrossRef]

60. Weng, L.; Dong, S.; Wang, S.; Yi, L.; Geng, D. Macraenhth attenuates lipopolysaccharide-induced depressive-like behaviors by inhibiting neuroinflammation in prefrontal cortex. *Physiol. Behav.* **2019**, *204*, 33–40. [CrossRef]

61. Wang, Y.; Ni, J.; Zhai, L.; Gao, C.; Xie, L.; Zhao, L.; Yin, X. Inhibition of activated astrocyte ameliorates lipopolysaccharide-induced depressive-like behaviors. *J. Affect. Disord.* **2021**, *242*, 52–59. [CrossRef]

62. Virmani, G.; D’Almeida, P.; Nandi, A.; Marathe, S. Subfield-specific effects of chronic mild unpredictable stress on hippocampal astrocytes. *Eur. J. Neurosci.* **2021**, *54*, 5730–5746. [CrossRef]

63. Ryan, K.M.; Allers, K.A.; McLoughlin, D.M.; Harkin, A. Tryptophan metabolite concentrations in depressed patients before and after electroconvulsive therapy. *Brain. Behav. Immun.* **2020**, *83*, 153–162. [CrossRef]

64. Öztürk, M.; Yalın Sapmaz, Ş.; Kandemir, H.; Taneli, F.; Aydemir, Ö. The role of the kynurenine pathway and quinolinic acid in adolescent major depressive disorder. *Int. J. Clin. Pract.* **2021**, *75*, e13739. [CrossRef]

65. Hassanain, H.H.; Chon, S.Y.; Gupta, S.L. Differential regulation of human indoleamine 2,3-dioxygenase gene expression by interferons-γ and α. Analysis of the regulatory region of the gene and identification of an interferon-γ-inducible DNA-binding factor. *J. Biol. Chem.* **1993**, *268*, 5077–5084. [CrossRef]

66. Pariente, C.M.; Pearce, B.D.; Pisell, T.L.; Sanchez, C.I.; Po, C.; Su, C.; Miller, A.H. The proinflammatory cytokine, interleukin-1α, reduces glucocorticoid receptor translocation and function. *Endocrinology* **1999**, *140*, 4399–4366. [CrossRef]

67. Besedovsky, H.O.; del Rey, A.; Klusman, I.; Furukawa, H.; Kabiersch, A. Cytokines as modulators of the hypothalamus-pituitary-adrenal axis. *J. Steroid Biochem. Mol. Biol.* **1991**, *40*, 613–618. [CrossRef]

68. Lapchak, P.A.; Araujo, D.M.; Hefti, F. Systemic interleukin-1 beta decreases brain-derived neurotrophic factor messenger RNA expression in the rat hippocampal formation. *Neuroscience* **1993**, *53*, 297–301. [CrossRef]

69. Kaneko, N.; Kudo, K.; Mabuchi, T.; Takemoto, K.; Fujimaki, K.; Wati, H.; Iguchi, H.; Tezuka, H.; Kanba, S. Suppression of cell proliferation by interferon-alpha through interleukin-1 production in adult rat dentate gyrus. *Neuropsychopharmacology* **2006**, *31*, 2619–2626. [CrossRef]

70. Zhang, J.; Hoedt, E.C.; Liu, Q.; Berendsen, E.; Teh, J.J.; Hamilton, A.; O’Brien, A.W.; Ching, J.Y.L.; Wei, H.; Yang, K.; et al. Elucidation of *Proteus mirabilis* as a key bacterium in Crohn’s disease inflammation. *Gastroenterology* **2021**, *160*, 317–330. [CrossRef] [PubMed]

71. Engevik, M.A.; Danhof, H.A.; Ruan, W.; Engevik, A.C.; Chang-Graham, A.L.; Engevik, K.A.; Shi, Z.; Zhao, Y.; Brand, C.K.; Krystofiak, E.S.; et al. *Fusobacterium nucleatum* secretes outer membrane vesicles and promotes intestinal inflammation. *MBio* **2012**, *12*, e02706-20. [CrossRef]

72. Matsumoto, S.; Hara, T.; Hori, T.; Mitsuyama, K.; Nagaoka, M.; Tomiyasu, N.; Suzuki, A.; Sata, M. Probiotic *Lactobacillus* induces improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells. *Clin. Exp. Immunol.* **2005**, *140*, 417–426. [CrossRef]

73. Liu, Q.; Lu, W.; Tian, F.; Zhao, J.; Zhang, H.; Hong, K.; Yu, L. *Akernansa muciniphila* exerts strain-specific effects on DSS-induced ulcerative colitis in mice. *Front. Cell. Infect. Microbiol.* **2021**, *11*, 698914. [CrossRef] [PubMed]

74. Segain, J.P.; Raingeard de la Bélitre, D.; Bourreille, A.; Leray, V.; Gervois, N.; Rosales, C.; Ferrier, L.; Bonnet, C.; Blottière, H.M.; Galmiche, J.P. Butyrate inhibits inflammatory responses through NFkappaB inhibition: Implications for Crohn’s disease. *Gut* **2000**, *47*, 397–403. [CrossRef] [PubMed]

75. Tedelind, S.; Westberg, F.; Kjerulf, M.; Vidal, A. Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: A study with relevance to inflammatory bowel disease. *World J. Gastroenterol.* **2007**, *13*, 2826–2832. [CrossRef] [PubMed]

76. Furusawa, Y.; Obata, Y.; Fukuda, S.; Endo, T.A.; Nakato, G.; Takahashi, D.; Nakaniishi, Y.; Uetake, C.; Kato, K.; Kato, T.; et al. Colminal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. *Nature* **2013**, *504*, 446–450. [CrossRef] [PubMed]

77. Duan, C.; Huang, L.; Zhang, C.; Zhang, L.; Xia, X.; Zhong, Z.; Wang, B.; Wang, Y.; Man Hoi, M.P.; Ding, W.; et al. Gut commensal-derived butyrate reverses obesity-induced social deficits and anxiety-like behaviors via regulation of microglial homeostasis. *Eur. J. Pharmacol.* **2021**, *908*, 174338. [CrossRef]

78. Wang, W.; Lv, S.; Zhou, Y.; Fu, J.; Li, C.; Liu, P. Tumor necrosis factor-α affects blood-brain barrier permeability in acetaminophen-induced acute liver failure. *Eur. J. Gastroenterol. Hepatol.* **2011**, *23*, 552–558. [CrossRef]
98. Evans, M.C.; Anderson, G.M. Dopamine neuron-restricted leptin receptor signaling reduces some aspects of food reward but...

88. Silva, D.A.; da Silva Freire Coutinho, E.; Ferriani, L.O.; Viana, M.C. Depression subtypes and obesity in adults: A systematic review and meta-analysis. "Anxiety- and depression-like behaviors induced by chronic unpredictable mild stress in rodents. Proc. Natl. Acad. Sci. USA 2005, 102, 292–297. [CrossRef] [PubMed]

92. Horne, R.; Foster, J.A. Metabolic and microbiota measures as peripheral biomarkers in major depressive disorder. Prog. Neuro-Psychopharmacology Biol. Psychiatry 2020, 111, 110351. [CrossRef] [PubMed]

85. Ogawa, Y.; Miyoshi, C.; Obana, N.; Yajima, K.; Hotta-Hirashima, N.; Ikkyu, A.; Kanno, S.; Soga, T.; Fukuda, S.; Yanagisawa, M. Gut microbiota depletion by chronic antibiotic treatment alters the sleep/wake architecture and sleep EEG power spectra in mice. Sci. Rep. 2020, 10, 19554. [CrossRef] [PubMed]

90. Duarte-Silva, E.; de Melo, M.G.; Maes, M.; Filho, A.J.M.C.; Macedo, D.; Peixoto, C.A. Shared metabolic and neuroimmune biomarkers on sleep and appetite in drug free patients with major depression: A systematic review and meta-analysis. J. Affect. Disord. 2020, 267, 78–85. [CrossRef] [PubMed]

84. Liu, Z.; Liu, R.; Zhang, Y.; Zhang, R.; Liang, L.; Wang, Y.; Wei, Y.; Zhu, R.; Wang, F. Association between perceived stress and depression among medical students during the outbreak of COVID-19: The mediating role of insomnia. J. Affect. Disord. 2021, 292, 89–94. [CrossRef] [PubMed]

80. Liu, Y.; Zhang, S.; Li, X.; Liu, E.; Wang, X.; Zhou, Q.; Ye, J.; Wang, J.Z. Peripheral inflammation promotes brain tau transmission and exacerbates the obesity of leptin receptor-deficient male mice. Endocrinology 2017, 158, 4246–4256. [CrossRef] [PubMed]

94. Kluge, M.; Schüssler, P.; Dresler, M.; Schmidt, D.; Yassouridis, A.; Uhr, M.; Steiger, A. Effects of ghrelin on psychopathology, sleep and secretion of cortisol and growth hormone in patients with major depression. J. Psychiatr. Res. 2011, 45, 421–426. [CrossRef] [PubMed]

99. Wilson, M.E.; Fisher, J.; Brown, J. Chronic subcutaneous leptin infusion diminishes the responsiveness of the hypothalamic-pituitary-adrenal (HPA) axis in female rhesus monkeys. Physiol. Behav. 2005, 84, 449–458. [CrossRef] [PubMed]

100. Schmid, D.A.; Held, K.; Ising, M.; Uhr, M.; Weikel, J.C.; Steiger, A. Ghrelin stimulates appetite, imagination of food, GH, ACTH, and cortisol, but does not affect leptin in normal controls. Neuropsychopharmacology 2005, 30, 1187–1192. [CrossRef] [PubMed]

101. Huang, H.-J.; Zhu, X.-C.; Han, Q.-Q.; Wang, Y.-L.; Yue, N.; Wang, J.; Yu, R.; Li, B.; Wu, G.-C.; Liu, Q.; et al. Ghrelin alleviates anxiety- and depression-like behaviors induced by chronic unpredictable mild stress in rodents. Behav. Brain Res. 2017, 326, 33–43. [CrossRef]
102. Morimoto, I.; Yamamoto, S.; Kai, K.; Fujihira, T.; Morita, E.; Eto, S. Centrally administered murine-leptin stimulates the hypothalamus-pituitary-adrenal axis through arginine-vasopressin. *Neuroendocrinology* **2000**, *71*, 366–374. [CrossRef]

103. Björklund, A.; Wiklund, L. Mechanisms of degrowth of the bulbospinal serotonin system following 5,6-dihydroxytryptamine induced axotomy. I. Biochemical correlates. *Brain Res.* **1980**, *191*, 109–127. [CrossRef]

104. Leibowitz, S.F.; Shor-Possner, G. Brain serotonin and eating behavior. *Appetite* **1986**, *7*, 1–14. [CrossRef]

105. Cameron, O.G.; Nesse, R.M. Systemic hormonal and physiological abnormalities in anxiety disorders. *Psychoneuroendocrinology* **1988**, *13*, 287–307. [CrossRef]

106. Hoebel, B.G.; Hernandez, L.; Schwartz, D.H.; Mark, G.P.; Hunter, G.A. Microdialysis studies of brain norepinephrine, serotonin, dopamine release during eating and drinking behavior. Theoretical and clinical implications. *Ann. N. Y. Acad. Sci.* **1989**, *575*, 171–191, discussion 192–193. [CrossRef] [PubMed]

107. Schloss, P.; Williams, D.C. The serotonin transporter: A primary target for antidepressant drugs. *J. Psychopharmacol.* **1998**, *12*, 115–121. [CrossRef]

108. Gallopin, T.; Fort, P.; Eggermann, E.; Cauli, B.; Luppi, P.H.; Rossier, J.; Audinat, E.; Mühlethaler, M.; Serafin, M. Identification of sleep-promoting neurons in vitro. *Nature* **2000**, *404*, 992–995. [CrossRef] [PubMed]

109. Morishima, M.; Harada, N.; Hara, S.; Sano, A.; Seno, H.; Takahashi, A.; Morita, Y.; Nakaya, Y. Monoamine oxidase A activity and norepinephrine level in hippocampus determine hyperwheel running in SPORTS rats. *Neuropsychopharmacology* **2006**, *31*, 2627–2638. [CrossRef]

110. Lammel, S.; Lim, B.K.; Malenka, R.C. Reward and aversion in a heterogeneous midbrain dopamine system. *Neuropsychopharmacology* **2014**, *76*, 351–359. [CrossRef] [PubMed]

111. Rajkowski, G.; D’Wyer, G.; Teleki, Z.; Stockmeier, C.A.; Miguel-Hidalgo, J.J. GABAergic neurons immunoreactive for calcium binding proteins are reduced in the prefrontal cortex in major depression. *Neuropsychopharmacology* **2007**, *32*, 471–482. [CrossRef]

112. Mann, J.J.; Oquendo, M.A.; Watson, K.T.; Boldrini, M.; Malone, K.M.; Ellis, S.P.; Sullivan, G.; Cooper, T.B.; Xie, S.; Currier, D. Anxiety in major depression and cerebrospinal fluid free gamma-aminobutyric acid. *Depress. Anxiety* **2014**, *31*, 814–821. [CrossRef] [PubMed]

113. Zhang, X.; Liu, Y.; Hong, X.; Li, X.; Meshul, C.K.; Moore, C.; Yang, Y.; Han, Y.; Li, W.G.; Qi, X.; et al. NG2 glia-derived GABA release tunes inhibitory synapses and contributes to stress-induced anxiety. *Nat. Commun.* **2021**, *12*, 5740. [CrossRef] [PubMed]

114. Lowes, D.C.; Chamberlin, L.A.; Kretsga, L.N.; Holt, E.S.; Abbas, A.I.; Park, A.J.; Yusufova, L.; Bretton, Z.H.; Firdous, A.; Enikolopov, A.G.; et al. Ventral tegmental area GABA neurons mediate stress-induced blunted reward-seeking in mice. *Nat. Commun.* **2021**, *12*, 3539. [CrossRef] [PubMed]

115. Farrell, M.R.; Esteban, J.S.D.; Faget, L.; Floresco, S.B.; Hnasko, T.S.; Mahler, S.V. Ventral pallidum GABA neurons mediate motivation underlying risky choice. *J. Neurosci.* **2021**, *41*, 4500–4513. [CrossRef]

116. Petty, F.; Trivedi, M.H.; Fulton, M.; John Rush, A. Benzodiazepines as antidepressants: Does GABA play a role in depression? *Biol. Psychiatry* **1995**, *38*, 578–591. [CrossRef]

117. Shima, T.; Fukushima, K.; Setoyama, H.; Imaoka, A.; Matsumoto, S.; Hara, T.; Suda, K.; Umesaki, Y. Differential effects of two probiotic strains with different bacteriological properties on intestinal gene expression, with special reference to indigenous Clostridium ramnosum regulates enterochromaffin cell development and serotonin release. *Sci. Rep.* **2019**, *9*, 1177. [CrossRef]

118. Mandić, A.D.; Woting, A.; Jaenicke, T.; Sander, A.; Sabrowski, W.; Rolle-Kampczyk, U.; von Bergen, M.; Blaut, M. *Bifidobacterium dentium* regulates enterochromaffin cell development and serotonin release. *FEMS Immunol. Med. Microbiol.* **2019**, *76*, 69–77. [CrossRef]

119. Engevik, M.A.; Endres, B.T.; et al. Human-derived *Bifidobacterium ramosum* regulates enterochromaffin cell development and serotonin release. *Sci. Rep.* **2019**, *9*, 1177. [CrossRef]

120. Asano, Y.; Hiramoto, T.; Nishino, R.; Aiba, Y.; Kimura, T.; Yoshihara, K.; Koga, Y.; Sudo, N. Critical role of gut microbiota in the production of biologically active, free catecholamines in the gut lumen of mice. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2012**, *303*, 1288–1295. [CrossRef] [PubMed]

121. Hata, T.; Asano, Y.; Yoshihara, K.; Kimura-Todani, T.; Miyata, N.; Zhang, X.T.; Takakura, S.; Aiba, Y.; Koga, Y.; Sudo, N. Regulation of gut luminal serotonin by commensal microbiota in mice. *PLoS ONE* **2017**, *12*, e0180745. [CrossRef]

122. Strandwitz, P. Neurotransmitter modulation by the gut microbiota. *Brain Res. 2018*, *1693*, 129–133. [CrossRef]

123. Yogeswara, I.B.A.; Maneerat, S.; Haltrich, D. Glutamate decarboxylase from lactic acid bacteria—A key enzyme in GABA synthesis. *Microorganisms* **2020**, *8*, 1923. [CrossRef]

124. Mizuno, S.; Masaoka, T.; Naganuma, M.; Kishimoto, T.; Kitazawa, M.; Kurokawa, S.; Nakashima, M.; Takeshita, K.; Suda, W.; Mimura, M.; et al. *Bifidobacterium*-rich fecal donor may be a positive predictor for successful fecal microbiota transplantation in patients with irritable bowel syndrome. *Digestion* **2017**, *96*, 29–38. [CrossRef]

125. Huang, H.L.; Chen, H.T.; Luo, Q.L.; Xu, H.M.; He, J.; Li, Y.Q.; Zhou, Y.L.; Yao, F.; Nie, Y.Q.; Zhou, Y.J. Relief of irritable bowel syndrome by fecal microbiota transplantation is associated with changes in diversity and composition of the gut microbiota. *J. Dig. Dis.* **2019**, *20*, 401–408. [CrossRef] [PubMed]

126. Dinan, T.G.; Stanton, C.; Cryan, J.F. Psychobiotics: A novel class of psychotropic. *Biol. Psychiatry* **2013**, *74*, 720–726. [CrossRef] [PubMed]
127. Mohammad, A.A.; Jazayeri, S.; Khosravi-Darani, K.; Solati, Z.; Mohammadpour, N.; Asemi, Z.; Adab, Z.; Djalali, M.; Tehrani-Dooost, M.; Hosseini, M.; et al. The effects of probiotics on mental health and hypothalamic-pituitary-adrenal axis: A randomized, double-blind, placebo-controlled trial in petrochemical workers. *Nutr. Neurosci.* 2016, 19, 387–395. [CrossRef]

128. Pinto-Sanchez, M.I.; Hall, G.B.; Ghajar, K.; Nardelli, A.; Bolino, C.; Lau, J.T.; Martin, F.-P.; Cominetti, O.; Welsh, C.; Rieder, A.; et al. Probiotic *Bifidobacterium longum* NCC2801 reduces depression scores and alters brain activity: A pilot study in patients with irritable bowel syndrome. *Gastroenterology* 2017, 153, 448–459. [CrossRef] [PubMed]

129. Benton, D.; Williams, C.; Brown, A. Impact of consuming a milk drink containing a probiotic on mood and cognition. *Eur. J. Clin. Nutr.* 2007, 61, 355–361. [CrossRef] [PubMed]

130. Ota, M.; Kikuchi-Hayakawa, H.; Ogura, J.; Ishikawa, H.; Nomogida, Y.; Ota, M.; Hidese, S.; Ishida, I.; Aida, M.; Matsuda, K.; et al. Effect of *Lactobacillus paracasei* strain Shirota on improvement in depressive symptoms, and its association with abundance of *Actinobacteria* in gut microbiota. *Microorganisms* 2021, 9, 1026. [CrossRef] [PubMed]

131. Nishida, K.; Sawada, D.; Kuwano, Y.; Tanaka, H.; Sugawara, T.; Aoki, Y.; Fujiwara, S.; Rokutan, K. Daily administration of paraprobiotic *Lactobacillus gasseri* CP2305 ameliorates chronic stress-associated symptoms in Japanese medical students. *J. Funct. Foods* 2017, 36, 112–121. [CrossRef] [PubMed]

132. Tanida, M.; Yamano, T.; Maeda, K.; Okumura, N.; Fukushima, Y.; Nagai, K. Effects of intraduodenal injection of *Lactobacillus johnsonii* La1 on renal sympathetic nerve activity and blood pressure in urethane-anesthetized rats. *Neurosci. Lett.* 2005, 389, 109–114. [CrossRef] [PubMed]

133. Tanida, M.; Takada, M.; Kato-Kataoka, A.; Kawai, M.; Miyazaki, K.; Shibamoto, T. Intragastric injection of *Lactobacillus casei* strain Shirota suppressed spleen sympathetic activation by central corticotrophin-releasing factor or peripheral 2-deoxy-d-glucose in anesthetized rats. *Neurosci. Lett.* 2016, 619, 114–120. [CrossRef] [PubMed]

134. Nakaita, Y.; Kaneda, H.; Shigyo, T. Heat-killed *Lactobacillus brevis* SBC8803 induces serotonin release from intestinal cells. *Food Nutr. Sci.* 2013, 4, 767–771. [CrossRef]

135. Sun, J.; Wang, F.; Hu, X.; Yang, C.; Xu, H.; Yao, Y.; Liu, J. *Clostridium butyricum* attenuates chronic unpredictable mild stress-induced depressive-like behavior in mice via the gut-brain axis. *J. Agric. Food Chem.* 2018, 66, 8415–8421. [CrossRef]

136. Hao, Z.; Wang, W.; Guo, R.; Liu, H. *Faecalibacterium prausnitzii* (ATCC 27766) has preventive and therapeutic effects on chronic unpredictable mild stress-induced depression-like and anxiety-like behavior in rats. *Psychoneuroendocrinology* 2019, 104, 132–142. [CrossRef]

137. Miyao, K.; Tanaka, Y.; Waki, R.; Hashioka, S.; Hayashi, M.; Nagahama, M.; Okazaki, S.; Yamashita, S.; Miura, S.; Miki, H.; et al. *Clostridium butyricum* MIYAIRI 588 as adjunctive therapy for treatment-resistant major depressive disorder: A prospective open-label trial. *Clin. Neuropsychol.* 2018, 41, 151–155. [CrossRef]

138. Shetty, S.A.; Boeren, S.; Bui, T.P.N.; Smidt, H.; de Vos, W.M. Unravelling lactate-acetate and sugar conversion into butyrate by intestinal *Anaerobutyricum* and *Anaerostipes* species by comparative proteogenomics. *Environ. Microbiol.* 2020, 22, 4863–4875. [CrossRef]

139. Tian, P.; Wang, G.; Zhao, J.; Zhang, H.; Chen, W. *Bifidobacterium* with the role of 5-hydroxytryptophan synthesis regulation alleviates the symptom of depression and related microbiota dysbiosis. *J. Nutr. Biochem.* 2019, 66, 43–51. [CrossRef]

140. Romo-Araiza, A.; Gutiérrez-Salmeán, G.; Galván, E.J.; Hernández-Frausto, M.; Herrera-López, G.; Romo-Parra, H.; García-Contreras, V.; Fernández-Presas, A.M.; Jasso-Chávez, R.; Borlongan, C.V.; et al. Probiotics and prebiotics as a therapeutic strategy to improve memory in a model of middle-aged rats. *Front. Aging Neurosci.* 2018, 10, 416. [CrossRef] [PubMed]

141. Srivastav, S.; Neupane, S.; Bhurpel, S.; Katila, N.; Maharan, S.; Choi, H.; Hong, J.T.; Choi, D.Y. Probiotics mixture increases butyrate, and subsequently rescues the nigral dopaminergic neurons from MPTP and rotenone-induced neurotoxicity. *J. Nutr. Biochem.* 2019, 69, 73–86. [CrossRef] [PubMed]

142. Wei, G.Z.; Martin, K.A.; Xing, P.Y.; Agrawal, R.; Whiley, L.; Wood, T.K.; Hejndorf, S.; Ng, Y.Z.; Low, J.Z.Y.; Rossant, J.; et al. Tryptophan-metabolizing gut microbes regulate adult neurogenesis via the aryl hydrocarbon receptor. *Proc. Natl. Acad. Sci. USA* 2021, 118, e2021091118. [CrossRef] [PubMed]

143. Lin, C.-J.; Wu, V.; Wu, P.-C.; Wu, C.-J. Meta-analysis of the associations of p-cresyl sulfate (PCS) and indoxyl sulfate (IS) with cardiovascular events and all-cause mortality in patients with chronic renal failure. *PLoS ONE* 2015, 10, e0132589. [CrossRef] [PubMed]

144. Sokol, H.; Pigneur, B.; Watterlot, L.; Lakkhdari, O.; Bermudez-Humaran, L.G.; Grattardoux, J.-J.; Blugeon, S.; Bridonneau, C.; Furet, J.-P.; Corthier, G.; et al. *Faecalibacterium prausnitzii* is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. *Proc. Natl. Acad. Sci. USA* 2008, 105, 16731–16736. [CrossRef] [PubMed]

145. Zhao, H.; Xu, H.; Chen, S.; He, J.; Zhou, Y.; Nie, Y. Systematic review and meta-analysis of the role of *Faecalibacterium prausnitzii* alteration in inflammatory bowel disease. *J. Gastroenterol. Hepatol.* 2021, 36, 320–328. [CrossRef]

146. Purton, T.; Staskova, L.; Lane, M.M.; Dawson, S.L.; West, M.; Firth, J.; Clarke, G.; Cryan, J.F.; Berk, M.; O’Neil, A.; et al. Prebiotic and probiotic supplementation and the tryptophan-kynurenine pathway: A systematic review and meta analysis. *Neurosci. Biobehav. Rev.* 2021, 123, 1–13. [CrossRef]

147. Rudzki, L.; Ostrowska, L.; Pawlak, D.; Malus, A.; Pawlak, K.; Waszkiewicz, N.; Szulc, A. Probiotic *Lactobacillus Plantarum* 299v decreases kynurenine concentration and improves cognitive functions in patients with major depression: A double-blind, randomized, placebo controlled study. *Psychoneuroendocrinology* 2019, 100, 213–222. [CrossRef] [PubMed]
148. Kazemi, A.; Noorbala, A.A.; Azam, K.; Eskandari, M.H.; Djafarian, K. Effect of probiotic and prebiotic vs placebo on psychological outcomes in patients with major depressive disorder: A randomized clinical trial. *Clin. Nutr.* 2019, 38, 522–528. [CrossRef] [PubMed]

149. Khalyfa, A.; Ericsson, A.; Qiao, Z.; Almendros, I.; Farré, R.; Gozal, D. Circulating exosomes and gut microbiome induced insulin resistance in mice exposed to intermittent hypoxia: Effects of physical activity. *EBioMedicine* 2021, 64, 103208. [CrossRef]

150. Trindade, L.M.; Torres, L.; Matos, I.D.; Miranda, V.C.; de Jesus, L.C.L.; Cacvalcante, G.; de Souza Oliveira, J.J.; Cassali, G.D.; Mancha-Agresti, P.; de Carvalho Azevedo, V.A.; et al. Paraprobiotic *Lactasebacillus rhamnosus* protects intestinal damage in an experimental murine model of mucositis. *Probiotics Antimicrob. Proteins* 2021. [CrossRef]

151. Sindhu, K.N.C.; Sowmyanarayanan, T.V.; Paul, A.; Babji, S.; Ajampur, S.S.R.; Priyadarshini, S.; Sarkar, R.; Balasubramanian, K.A.; Wanke, C.A.; Ward, H.D.; et al. Immune response and intestinal permeability in children with acute gastroenteritis treated with *Lactobacillus rhamnosus* GG: A randomized, double-blind, placebo-controlled trial. *Clin. Infect. Dis.* 2014, 58, 1107–1115. [CrossRef] [PubMed]

152. Wang, H.B.; Wang, P.Y.; Wang, X.; Wan, Y.L.; Liu, Y.C. Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein claudin-1 transcription. *Dig. Dis. Sci.* 2012, 57, 3126–3135. [CrossRef]

153. Zhao, H.; Jia, L.; Yan, Q.; Deng, Q.; Wei, B. Effect of *Clostridium butyricum* and butyrate on intestinal barrier functions: Study of a rat model of severe acute pancreatitis with intra-abdominal hypertension. *Front. Physiol.* 2020, 11, 561061. [CrossRef]

154. Ait-Belgnaoui, A.; Han, W.; Lamine, F.; Eutamene, H.; Fioramonti, J.; Bueno, L.; Theodorou, V. *Lactobacillus farciminis* treatment suppresses stress induced visceral hypersensitivity: A possible action through interaction with epithelial cell cytoskeleton contraction. *Gut* 2006, 55, 1090–1094. [CrossRef]

155. Seth, A.; Yan, F.; Polk, D.B.; Rao, R.K. Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and MAP kinase-dependent mechanism. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2008, 294, G1060–G1069. [CrossRef] [PubMed]

156. Gotteland, M.; Cruchet, S.; Verbeke, S. Effect of *Lactobacillus* ingestion on the gastrointestinal mucosal barrier alterations induced by indometacin in humans. *Aliment. Pharmacol. Ther.* 2001, 15, 11–17. [CrossRef] [PubMed]

157. Karczewski, J.; Troost, F.J.; Konings, I.; Dekker, J.; Kleerbezem, M.; Brummer, R.J.M.; Wells, J.M. Regulation of human epithelial tight junction proteins by *Lactobacillus plantarum* in vivo and protective effects on the epithelial barrier. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2010, 298, 851–859. [CrossRef] [PubMed]

158. Krumbeck, J.A.; Rasmussen, H.E.; Hutkins, R.W.; Clarke, J.; Shawron, K.; Keshavarzian, A.; Walter, J. Probiotic *Bifidobacterium* strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as symbiotics. *Microbiome* 2018, 6, 121. [CrossRef]

159. Suzuki, K.; Nakamura, K.; Shimizu, Y.; Yokoi, Y.; Ohira, S.; Hagiwara, M.; Wang, Y.; Song, Y.; Aizawa, T.; Ayabe, T. Decrease of α-defensin impairs intestinal metabolite homeostasis via dysbiosis in mouse chronic social defeat stress model. *Sci. Rep.* 2021, 11, 9915. [CrossRef]

160. Autry, A.E.; Montegia, L.M. Brain-derived neurotrophic factor and neuropsychiatric disorders. *Pharmacol. Rev.* 2012, 64, 238–258. [CrossRef] [PubMed]

161. Moreno-Jiménez, E.P.; Flor-García, M.; Terreros-Roncal, J.; Rábano, A.; Cafini, F.; Pallas-Bazarra, N.; Ávila, J.; Llorens-Martín, M. Adult hippocampal neurogenesis is abundant in neurologically healthy subjects and drops sharply in patients with Alzheimer’s disease. *Nat. Med.* 2019, 25, 554–560. [CrossRef]

162. Radtke, F.A.; Chapman, G.; Hall, J.; Syed, Y.A. Modulating neuroinflammation to treat neuropsychiatric disorders. *Biomed Res. Int.* 2017, 2017, 507176. [CrossRef] [PubMed]